Des

ign:

Re

B, w

ww

.re-b

.ch

Sponsor:

Personalized MedicineSymposium

www.lifescience-businessnetwork.ch

September 13th 2011 8.30 am– 4.30 pm Auditorium TECHNOPARK® Zurich

The Life Science Zurich Business Network is a newly established platform with a single point of contact to promote co-operation between the Life Science stakeholders in academia, industry and the public sector in the Greater Zurich area as well as with other life science centers in Switzerland and across the world.

The Life Science Zurich Business Network is pleased to announce its first symposium. This year’s topic is on Personalized Medicine.

Summary Humans differ not only in their appearance but also in their responses to medication and the susceptibility to diseases. These differences are determined to a large extent by our genome that is stored in our cells in the form of DNA. The deciphering of the human genome sequence cost 3 billion Swiss Francs 10 years ago. Owing to dramatic technical progress in DNA sequencing the determination of the genome sequence of individual persons will soon cost less than 1,000 Swiss Francs. This will permit individuals to learn more about themselves and their ancestry. By providing their anonymized genome sequence, health and medical records to medical research they can make an active contribution to the understanding and treatment of diseases. Over the past 10 years we have learnt that only the comparison of millions of such datasets will permit physicians to make more reliable diagnoses and recommendation for disease prevention. As we deposit our money safely in the bank and expect interests, we may in the near future deposit our genome sequence and medical records to obtain personalized health recommendations and medical treatment. The opportunities and the challenges associated with the availability of personal genome data will be discussed at the Symposium «Personalized Medicine» that is organized by Life Science Zurich Business Network on September 13th, 2011 at TECHNOPARK® Zurich.

Life Science Zurich Business Network Symposium on Personalized Medicine September 13th, 2011 at TECHNOPARK® Zurich

am

8.30 Registration & Welcome Coffee

9 Welcome Address Thomas Heiniger, Health Dept.

Canton Zurich

9.10 Introductory Keynote Address Ernst Hafen, ETH Zurich 9.30 Genomic information and the healthcare consumer Uta Francke, Stanford University

School of Medicine

10 Translational genomics and health outcomes: a new research discipline Robert C. Green, Harvard Medical School

10.30 Coffee Break

11 Integrated prospective healthcare and research James Allen Heywood, PatientsLikeMe

11.30 Immuntherapy of neurodegenerative diseases Roger Nitsch, Neurimmune &

University of Zurich

12 Healthy Business Lunch

pm

1 The molecular personalisation of medicine, future vision or immediate necessity? Jonathan Knowles, Caris Life Science

1.30 Pioneering personalized healthcare through pharma partnering: a case study in companion diagnostic co-development Stephen Little, Qiagen

2 Coffee Break

2.30 Panel Discussion Speakers and Esther Dyson (23andMe); Moderator: Mathis Brauchbar,

Advocacy

3.30 Closing Remarks Ernst Hafen, ETH Zurich

3.45 Networking Aperitif/Coffee

4.30 End

Please register for the symposium:

Tuesday September 13th, 2011 Auditorium TECHNOPARK® Zurich, Technoparkstr. 1, Zurich

www.lifescience-businessnetwork.ch

Biographies of Invited Speakers and the Moderator

Thomas Heiniger, Dr. iur., was elected as a member of the Government Council of the Canton of Zurich in 2007, where he officiates as Head of the Health Department. Previously, he worked as a partner with a commercial law firm. He also was a member of the Cantonal Government for the Radical Party (1999–2007) and Mayor of Adliswil (1994–2007). Thomas Heiniger finished his studies at the University of Zurich, faculty of law, with a licentiate degree (1982), received his PhD (1985) and became an accredited attorney at law in 1987. In addition, he successfully completed training as a mediator IRP HSG (2005).

Ernst Hafen obtained his PhD from the Biocenter at the University of Basel in 1983. From 1984 to 1986 he worked at the University of California in Berkeley as a postdoctoral fellow before joining the University of Zurich as an assistant professor in 1987 and was promoted to full professor in 1997. From 2005 to 2006 he served as president of ETH Zürich. Since 2005 he holds professorship at the Institute of Molecular Systems Biology at ETH Zurich. Ernst Hafen has made several seminal contributions to the field of develop-mental biology and cell biology including the characte-rization of genes and the corresponding signaling pathways involved in cell fate specification and in the control of cell and body size. He has received several prizes and has served on the Editorial Boards of various journals and scientific committees. He is a co-founder of evalueSCIENCE, a privately held consulting company that offers reviews and second opinions on R&D projects by a standardized peer review process to life science companies, academic institutions and inves-tors. As a trained geneticist he has a strong interest in human genetics and personalized medicine.

Uta Francke, M.D. and Professor of Genetics and Pediatrics at Stanford University School of Medicine, is an internationally acclaimed genetics researcher and clinician, who has spent over 30 years conducting studies that have advanced the understanding of many inherited disorders at the molecular level. Dr. Francke has served as an advisor to and director of numerous professional organizations and societies. She has received a wide range of honors and awards, and served as editor or editorial board member of many scholarly publications. For 3 years, she worked as a consultant, and now she is Senior Medical Director, at the personal genomics company 23andMe, Inc. Dr. Francke received her medical degree at the Univer-sity Medical School in Munich, Germany. Prior to her appointment as Professor of Genetics and Howard Hughes Medical Investigator at Stanford in 1989, she held academic appointments at the University of California at San Diego and Yale University School of Medicine.

Robert C. Green, MD, MPH is a medical geneticist with a research focus in translational genomics and health outcomes. Dr. Green directs the NIH-funded REVEAL Study, in which a cross-disciplinary team has conducted 4 separate multi-center randomized clinical trials collectively enrolling 1100 individuals to explore emerging themes in translational genomics. Dr. Green also co-directs the first NIH-funded prospective study of personal genome services. He is a member of the NIH-funded Workgroup on Incidental Findings in genetic research, a Board Member of the Council for Responsible Genetics and a member of the Informed Cohort Oversight Boards for both the Children’s Hospital Boston Gene Partnership Program and the Coriell Personalized Medicine Collaborative. Dr. Green is currently Associate Director for Research of the Partners Center for Personalized Genetic Medicine and an Associate Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School.

Biographies of Invited Speakers and the Moderator

James Allen Heywood, is an MIT engineer with a background in product development and neuro-science. He entered the field of translational research when his 29 year old brother Stephen was diagnosed with ALS. He is the Chairman and Co-founder of PatientsLikeMe, a Web 2.0 company where patients can share in depth information about their condition (treatments, symptoms, outcomes) and real world experiences on managing their life changing diseases.PatientsLikeMe is working with the pharmaceutical industry, providers, non-profits and patients to improve medical care by better understanding these diseases and the patient experience. James Heywood founded ALS TDI, the world's first non-profit biotech-nology company, where he served as CEO from 1999 to 2007. Pioneering an open research model and industrialized therapeutic validation process, he led ALS TDI to become the world's largest ALS drug discovery program. He is an active advisor to companies and non-profits working to improve the way in which biomedical research is conducted.

Jonathan Knowles, PhD, was Head of Group Research and Member of the Executive Committee at Roche up to the end of 2009. Under his leadership, the company developed and implemented a strategy of highly effective therapies based on personalized healthcare and built one of the best pharma pipelines in the sector. Jonathan Knowles holds a Distinguished Professorship in Personalized Health care at FIMM (Finnish Institute for Molecular Medicine) at the Uni versity of Helsinki, was recently appointed Professor of Translational Medicine at EPFL in Switzerland, and has been appointed to a Visiting chair at the University of Oxford. Dr. Knowles attended Magdalen College School in Oxford and received a First Class Honours Degree in Molecular Genetics from the University of East Anglia in Norwich, England. He received his Ph.D. in Genetics of Mitochondria with Professor G. H. Beale F.R.S. from the University of Edinburgh in Scotland. From the beginning of 2010, Dr. Knowles joined the Board of Caris Life Sciences, an international cutting edge molecular diagnostics company based in Irving, Texas.

Roger M. Nitsch, MD, Professor at University of Zurich, is a founder and Director of Neurimmune. A neuroscientist with a background in medicine, Roger Nitsch is recognized as a key opinion leader in neurodegenerative disease research with more than 20 years of experience in Alzheimer’s disease research, and as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases. The Potamkin prize winner and Member of the German Academy of Sciences directs the Division of Psychiatry Research at the University of Zurich, Switzerland.

Stephen Little, PhD, Vice President Personalized Healthcare at Qiagen. Dr. Stephen Little is a leading figure in the global personalized healthcare and companion diagnostics industry. Co-founder and former CEO of DxS Ltd, Dr. Little led the company from its inception in 2001 to become the market leader in the provision of molecular diagnostics for cancer. In September 2009, DxS was acquired by QIAGEN, a global sample and assay company. DxS is now QIAGEN Manchester Ltd, a Center of Excellence in Companion Diagnostics operating worldwide. Dr. Little has over 20 years experience in the pharma ceutical and diagnostics sectors, and as VP of Personalized Health-care at QIAGEN he continues to help shaping the personalized medicine marketplace, championing the cause of pharmaceutical partnering and companion diagnostic provision in healthcare.

Biographies of Invited Speakers and the Moderator

Esther Dyson, 23andme, New York, a long-time catalyst of start-ups in information technology in the US and other markets, including Russia. Since selling my company, EDventure Holdings, to CNET Networks in 2004, I have taken on newer challenges in private aviation and space as well as in health care (as a director of 23andMe, a consumer genetics company).My IT investments have included Flickr and del.icio.us (both sold to Yahoo!), and Medstory (sold to Microsoft), as well as Meetup Inc., Eventful.com, Boxbe and Voxiva; I sit on the boards of the latter four companies. I'm also an active investor in air and space, with holdings in Space Adventures and Zero-G Corporation, as well as XCOR Aerospace, Constellation Services International, Coastal Technologies Group, Dopplr.com, Airship Ventures and Icon Aircraft. I do business under the (reclaimed) name of EDventure Holdings.

Mathis Brauchbar did his studies at the Uni versity of Basel where he obtained a master in molecular biology from the Biocenter. During his studies he started to work as a science writer for various news papers and magazines in Switzerland, Germany, France and Austria. In 1989, he founded Locher, Brauchbar & Partners AG (today: Locher, Schmill, Van Wezemael & Partner AG), an office for communication, consulting and planning in issues like health care, social security, energy and ecology. In 2001, Mathis Brauchbar co-founded advocacy ag, a communication and consulting dealing with public affairs and issues in health care and corporate social responsibility. Mathis Brauchbar also co-founded evalueSCIENCE (2008), a consultancy which offers its clients services involving a network of several hundred high-caliber specialists from around the world.